The stock price of Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) has surged by 5.84 when compared to previous closing price of 1.21, but the company has seen a 8.53% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-16 that NEW YORK, June 16, 2025 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial.
Is It Worth Investing in Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Right Now?
The stock has a 36-month beta value of 0.21. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCLI is 6.17M, and at present, short sellers hold a 8.70% of that float. On June 20, 2025, the average trading volume of BCLI was 1.28M shares.
BCLI’s Market Performance
BCLI stock saw an increase of 8.53% in the past week, with a monthly gain of 3.28% and a quarterly increase of -16.84%. The volatility ratio for the week is 8.39%, and the volatility levels for the last 30 days are 4.73% for Brainstorm Cell Therapeutics, Inc (BCLI). The simple moving average for the last 20 days is 10.59% for BCLI stock, with a simple moving average of -29.71% for the last 200 days.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at 15.33% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.59% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
The total capital return value is set at 1.64.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -12.63.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
To sum up, Brainstorm Cell Therapeutics, Inc (BCLI) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
